Table 1 Clinical characteristics of patients at baseline
Baseline characteristics | All patients (N = 18) |
|---|---|
Age: median (range), years | 63.5 (47–90) |
Sex, n (%) | |
 Male | 10 (55.5) |
 Female | 8 (44.5) |
ECOG performance status, n (%) | |
 0–1 | 14 (78) |
 2 | 4 (22) |
Lines of therapy prior to cryo (including ICI at time of cryo)a | |
 1 | 7 (39) |
 2 | 5 (28) |
 ≥3 | 6 (33) |
Type of ICI at time of ablation | |
 PD-1 inhibition (pembrolizumab, nivolumab) | 18 (100) |
Presence of CNS metastasis | |
Yes | 4 (22) |
No | 14 (78) |
LDH elevated above baseline prior to cryo | |
Yes | 9 (50%) |
No | 9 (50%) |
Best response to ICI prior to ablation | |
Partial response | 2 (12) |
Stable disease | 8 (47) |
Progressive disease | 7 (41) |
Duration of ICI prior to cryoablation | 105 days (55–1250 days) |
